GC
Drug
Celgene Corporation
Total Payments
$290,558
Transactions
21
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $263,405 | 17 | 0 |
| 2018 | $27,153 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $290,558 | 21 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (GC-LTFU-001) | Celgene Corporation | $263,405 | 0 |
| GC-LTFU-001 - Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Celgene Corporation | $27,153 | 0 |
Top Doctors Receiving Payments for GC
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $290,558 | 21 |
Ad
Manufacturing Companies
- Celgene Corporation $290,558
Product Information
- Type Drug
- Total Payments $290,558
- Total Doctors 0
- Transactions 21
About GC
GC is a drug associated with $290,558 in payments to 0 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $263,405 was paid across 17 transactions to 0 doctors.
The most common payment nature for GC is "Unspecified" ($290,558, 100.0% of total).
GC is associated with 2 research studies, including "Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (GC-LTFU-001)" ($263,405).